Picture of Effector Therapeutics logo

EFTR — Effector Therapeutics News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareHighly SpeculativeMicro Cap

Brief: eFFECTOR Therapeutics Says Zotatifin Generally Well Tolerated As Dose Escalation Continues

Dec 8 (Reuters) - eFFECTOR Therapeutics Inc  EFTR.O :
    * EFFECTOR THERAPEUTICS ANNOUNCES NEW POSITIVE INTERIM DATA
FROM
DOSE ESCALATION AND PHASE 2 EXPANSION COHORTS OF ZOTATIFIN IN
ER+ METASTATIC BREAST CANCER PATIENTS
    * EFFECTOR THERAPEUTICS INC: ZOTATIFIN GENERALLY WELL
TOLERATED AS
DOSE ESCALATION CONTINUES
    * EFFECTOR THERAPEUTICS INC- COMPANY EXPECTS TO REPORT
ADDITIONAL
DATA FROM DOSE ESCALATION IN FIRST HALF OF 2024
    * EFFECTOR THERAPEUTICS: CURRENTLY ENROLLING AT 0.28 MG/KG
IN ZF
DOUBLET EVALUATING ZOTATIFIN COMBINED WITH FULVESTRANT AND AT
0.1 MG/KG IN ZFA TRIPLET

Source text for Eikon:  ID:nGNX4WZjlN 
Further company coverage:  EFTR.O 

 ((reuters.briefs@thomsonreuters.com;))

Recent news on Effector Therapeutics

See all news